Terms: = Bone cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
23 results:
1. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
2. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
3. Cell-based screen identifies porphyrins as fgfr3 activity inhibitors with therapeutic potential for achondroplasia and cancer.
Lin YW; Kao HJ; Chen WT; Kao CF; Wu JY; Chen YT; Lee YC
JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37824212
[TBL] [Abstract] [Full Text] [Related]
4. Erdafitinib in the treatment of Metastatic Urothelial Carcinoma.
Castro-Alonso FJ; Beas-Lozano E; Remolina-Bonilla YA; Flaig TW; Bourlon MT
Oncology (Williston Park); 2023 Jun; 37(6):256-261. PubMed ID: 37343207
[TBL] [Abstract] [Full Text] [Related]
5. Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.
Nakamura Y
Cells; 2021 Jun; 10(7):. PubMed ID: 34203430
[TBL] [Abstract] [Full Text] [Related]
6. A brief guide to pustular psoriasis for primary care providers.
Crowley JJ; Pariser DM; Yamauchi PS
Postgrad Med; 2021 Apr; 133(3):330-344. PubMed ID: 33118424
[TBL] [Abstract] [Full Text] [Related]
7. Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis.
Frieling JS; Li T; Tauro M; Lynch CC
Neoplasia; 2020 Oct; 22(10):511-521. PubMed ID: 32896761
[TBL] [Abstract] [Full Text] [Related]
8. Crouzon with Acanthosis Nigricans and Odontogenic Tumors: A Rare Form of Syndromic Craniosynostosis.
Xu W; McDonald-McGinn DM; Melchiorre AJ; Zackai EH; Bartlett SP; Taylor JA
Cleft Palate Craniofac J; 2018 Feb; 55(2):296-300. PubMed ID: 29351036
[TBL] [Abstract] [Full Text] [Related]
9. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
[TBL] [Abstract] [Full Text] [Related]
10. HDAC6 deficiency or inhibition blocks fgfr3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract] [Full Text] [Related]
11. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated fgfr3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract] [Full Text] [Related]
12. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
Lu G; Muddasani R; Orlowski RZ; Abruzzo LV; Qazilbash MH; You MJ; Wang Y; Zhao M; Chen S; Glitza IC; Medeiros LJ
Arch Pathol Lab Med; 2013 May; 137(5):625-31. PubMed ID: 23627452
[TBL] [Abstract] [Full Text] [Related]
13. Targeted therapy of multiple myeloma.
Dolloff NG; Talamo G
Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
[TBL] [Abstract] [Full Text] [Related]
14. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
[TBL] [Abstract] [Full Text] [Related]
15. fgfr3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract] [Full Text] [Related]
16. Bortezomib therapeutic effect is associated with expression and mutation of fgfr3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract] [Full Text] [Related]
17. achondroplasia: pathogenesis and implications for future treatment.
Laederich MB; Horton WA
Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
[TBL] [Abstract] [Full Text] [Related]
18. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
[TBL] [Abstract] [Full Text] [Related]
19. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract] [Full Text] [Related]
20. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract] [Full Text] [Related]
[Next]
